Phospholipase A2 receptor (PLA2R) antibodies


Suspicion of primary membranous nephropathy (PMN), previously idiopathic membranous nephropathy (IMN).


Indirect immunofluorescence (IIF) with PLA2R transfected cells for screening.

ELISA for quantification when positive IIF screening and for monitoring of treatment effect.


Indirect immunofluorescence (IIF): The result is given as negative or positive. A positive result is followed by quantification by ELISA.

ELISA: The result is given as negative, borderline or positive with a value.


Antibodies against PLA2R is a strong marker for primary membrane nephropathy (PMN). Antibodies against PLA2R lead to complement-activating immune complexes deposited on basal membrane in glomeruli with tissue damage and proteinuria as a consequence. Antibodies against PLA2R occur in serum in 75% of the PMN cases. Concentration of antibodies is associated with disease development and their concentration determination by ELISA (RU/ml) can be used to follow treatment effect.

In case of negative results, it is recommended to supplement with testing for antibodies against Thrombospondin Type 1 Domain Containing 7A (anti-THSD7A) which occurs in approximately 10% of anti-PLA2R negative PMN. Simultaneous presence of anti-PLA2R and anti-THSD7A antibodies is very unusual.

Read more about sampling

Packages and other tests

View other packages Glomerulonephritis (500), Primary Membranous Nephropathy (PMN) (584). View other tests ANA screen (HEp-2 cells), dsDNA antibodies, GBM antibodies (the Goodpasture antigen), MPO-ANCA (capture technique), MPO-ANCA (direct technique), PR3-ANCA (capture technique), PR3-ANCA (direct technique), Streptolysin O antibodies

Clinical studies